Enzo Biochem Steady Today At $1.93 After Earnings

Thursday, June 15, 2023 - Enzo Biochem (ENZ) reported downside earnings and upside revenues.

Enzo Biochem reported EPS loss of $0.31 per share. Profits fell 244% year-over-year after reporting an EPS loss of $0.09 per share in its year-ago quarter. The negative growth rate signals that the Healthcare company isn't performing well amid current economic conditions.

Revenues were upbeat at $16.1 million. That revenue figure represents a 38.57% decrease from the year ago quarter.

The stock is steady today at $1.93 after the report.

The firm's higher revenue growth to earnings signals that the firm has not been able to reduce costs and has seen its profit margin decrease.

Trading in the five days leading up to the report earned Enzo Biochem a Bearish Sentiment Rank from InvestorsObserver.

Prior to the report, InvestorsObserver gave the stock an overall score of 47.

Enzo Biochem Inc is a bioscience company. The firm manufactures, develops and sell their proprietary solutions and platforms to clinical laboratories, specialty clinics and researchers and physicians internationally. It focuses on delivering and applying its technology to produce products and services to allow its customers to meet their clinical needs. The company has Enzo clinical labs, Enzo life sciences, Enzo therapeutics operating segments. It derives the majority of its revenues from the Clinical lab's segment.